Chalcogen Bonded Directly To A Ring Carbon Of The 1,3-diazole Ring Patents (Class 546/273.7)
-
Publication number: 20030153766Abstract: The present invention relates to a production method of a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole.n′H2O (wherein n′ is about 0 to about 0.1) or a salt thereof, which characteristically includes crystallization from an organic solvent solution or suspension in which (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-benzimidazole.nH2O (wherein n is about 0.1 to about 1.0) or a salt thereof has been dissolved or suspended, and the like, and provides a convenient method for efficiently producing an optically active sulfoxide derivative having an extremely high enantiomer excess in high yield at an industrial large scale.Type: ApplicationFiled: November 7, 2002Publication date: August 14, 2003Inventors: Hideo Hashimoto, Hideaki Maruyama
-
Publication number: 20030096845Abstract: Compounds represented by formula (Ia) are disclosed by the invention, along with compositions and complexes thereof, optionally in combination with compounds of formula (Ib). Pharmaceutical formulations and methods of making and using such compounds are also disclosed.Type: ApplicationFiled: July 3, 2002Publication date: May 22, 2003Inventors: Robert R. Whittle, Frederick D. Sancillio, Grayson Walker Stowell, Douglas John Jenkins, Linda B. Whittall
-
Publication number: 20030088106Abstract: The present invention provides processes for purifying 6-methoxy omeprazole, products using such processes, pharmaceutical formulations using such products, and methods of using such products for gastric acid inhibition.Type: ApplicationFiled: April 20, 2001Publication date: May 8, 2003Inventors: Linda B. Whittall, Grayson Walker Stowell, Robert R. Whittle
-
Publication number: 20030045724Abstract: A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.Type: ApplicationFiled: September 13, 2002Publication date: March 6, 2003Inventors: Akira Fujishima, Isao Aoki, Keiji Kamiyama
-
Patent number: 6528509Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1-4, Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.Type: GrantFiled: October 5, 2001Date of Patent: March 4, 2003Assignee: Vertex Pharmacuticals, IncorporatedInventors: Michael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang, Robert Mashal
-
Publication number: 20030036554Abstract: Improved processes for preparing substituted 2-(2-pyridylmethyl)sulfinyl-1H-benzimidazoles are disclosed.Type: ApplicationFiled: February 4, 2002Publication date: February 20, 2003Inventors: Ilya Avrutov, Marioara Mendelovici
-
Publication number: 20030036656Abstract: The method for obtaining derivatives of [[(pyridil substituted)methyl]thio]benzomidazol (I), where each of R1, R3 and R4, independently of each other, is hydrogen, an alkyl, alkoxy or fluorinated alkoxy of 1 to 6 carbon atoms, and R2 is nitro, halogen, alkoxy or halogenated alkoxy of 1 to 6 carbon atoms, or a group —OR—(CH2)n—OR8, where n is an integer between 1 and 6 and R8 represents hydrogen or an alkyl group with 1 to 6 carbon atoms, which involves (a) reacting an N-oxide of a methylpyridine with an anhydride of activated carboxylic acid or of sulfonic acid, and (b) reacting the intermediate formed in stage (a) with a corresponding mercaptobenzomidazol. The compounds (I) are useful in the synthesis of derivatives of [[(pyridil substituted)methyl]sulfinyl]benzomidazol, such as omeprazol, lansoprazol, rabeprazol or pantoprazol.Type: ApplicationFiled: August 20, 2002Publication date: February 20, 2003Inventor: Ramon Berenguer Maimo
-
Patent number: 6511996Abstract: The present invention relates to a novel form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, known under the generic name omeprazole. More specifically, it relates to a novel crystalline form of the potassium salt of the (S)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole. The present invention also relates to processes for preparing such a form of the potassium salt of (S)-omeprazole and pharmaceutical compositions containing it.Type: GrantFiled: April 26, 2000Date of Patent: January 28, 2003Assignee: AstraZeneca ABInventor: Maths Nilsson
-
Patent number: 6506738Abstract: The present invention concerns antiviral compounds, their compositions, and use in the treatment of viral infections. More particularly, the invention provides benzimidazolone derivatives for the treatment of respiratory syncytial virus infection.Type: GrantFiled: September 14, 2001Date of Patent: January 14, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Kuo-Long Yu, Rita Civiello, Keith Combrink, Hatice Belgin Gulgeze, Bradley C. Pearce, Xiangdong Wang, Nicholas A. Meanwell, Yi Zhang
-
Patent number: 6503929Abstract: Nitrate salt compositions with anti-ulcer medicines having formula (A) and (B) wherein the (A) class compounds: R=H, OCH3, OCHF2; R1=CH3, OCH3; R2=H, CH3; R3=CH3, CH2—CF3, (CH2)3—OCH3; wherein the (B) class compounds: RI3, RI4 equal to or different from each other, are respectively free valence hydrogen, (1), —CH2—N(CH3)2; Y=S, N—RI6, CRI7RI8; X=O, S, N—RI1; RI2=H, CH3; n=0, 1; Z=N—CN, N—SO2NH2, CH—NO2 or formula (VIIA) RI5=H, —NH—CH3, NH2; RI6, RI7, RI8, RI1, equal to or different from each other, are hydrogen, free valence. The invention also comprises the methods for the preparation of above salts.Type: GrantFiled: August 29, 2000Date of Patent: January 7, 2003Assignee: Nicox S.A.Inventor: Piero Del Soldato
-
Publication number: 20030004190Abstract: The present invention relates to a novel process for the preparation of the magnesium salt of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole trihydrate, ie. S-omeprazole magnesium salt trihydrate. The present invention also relates to the S-omeprazole magnesium salt trihydrate prepared in accordance with the new process and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: ApplicationFiled: April 1, 2002Publication date: January 2, 2003Inventors: Anders Kronstrom, Eva Leander, Anders Mattson, Karin Jansson, Martin Bohlin
-
Patent number: 6489346Abstract: There is provided a solid pharmaceutical composition in a dosage form that is not enteric-coated, having active ingredients including a non-enteric coated proton pump inhibitor and at least one buffering agent. The proton pump inhibitor is omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole, or an enantiomer, isomer, derivative, free base, or salt thereof, in an amount of approximately 5 mg to approximately 300 mg; and the buffering agent is in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of proton pump inhibitor. The dosage form includes a suspension tablet, a chewable tablet, an effervescent powder, or an effervescent tablet. Also provided is a method for treating an acid-related gastrointestinal disorder in a subject in need thereof by administering to the subject a solid pharmaceutical composition.Type: GrantFiled: January 11, 2000Date of Patent: December 3, 2002Assignee: The Curators of the University of MissouriInventor: Jeffrey Owen Phillips
-
Publication number: 20020156103Abstract: The present invention provides processes for purifying 6-methoxy omeprazole, products using such processes, pharmaceutical formulations using such products, and methods of using such products for gastric acid inhibition.Type: ApplicationFiled: April 20, 2001Publication date: October 24, 2002Inventors: Linda B. Whittall, Grayson Walker Stowell, Robert R. Whittle
-
Publication number: 20020156284Abstract: The present invention relates to a novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, known under the generic name omeprazole. Further, the present invention also relates to the use of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole.Type: ApplicationFiled: February 13, 2002Publication date: October 24, 2002Inventors: Karin Lovqvist, Gunnel Sunden, David Noreland, Ingvar Ymen
-
Patent number: 6462058Abstract: A novel crystal of (R)-2-[[[3-methyl-4-(2, 2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.Type: GrantFiled: November 3, 2000Date of Patent: October 8, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Akira Fujishima, Isao Aoki, Keiji Kamiyama
-
Publication number: 20020111370Abstract: The present invention relates to novel compounds of Formula I, and pharmaceutically acceptable salts thereof, as antibacterial agents. The compounds of the present invention are nitric oxide releasing derivatives of proton pump inhibitors (NO-releasing PPIs). In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above. The invention also relates to new intermediates for use in the preparation of the novel compounds. Additionally the present invention relates to co-administration of NO-releasing PPIs with other known medicaments.Type: ApplicationFiled: December 20, 2001Publication date: August 15, 2002Inventors: Rolf Bergman, Arne Eek, Lars-Inge Olsson, Per Lindberg
-
Publication number: 20020103232Abstract: Compounds represented by formula (Ia) are disclosed by the invention, along with compositions and complexes thereof, optionally in combination with compounds of formula (Ib). Pharmaceutical formulations and methods of making and using such compounds are also disclosed.Type: ApplicationFiled: January 25, 2002Publication date: August 1, 2002Inventors: Robert R. Whittle, Frederick D. Sancilio, Grayson Walker Stowell, Douglas John Jenkins, Linda B. Whittall
-
Patent number: 6423846Abstract: Lansoprazole of formula (I) can be produced economically in a high yield using a simple, two-step method comprising reacting hydroxymethylpyridine and benzimidazole starting materials in the presence of a phosphine compound and a dialkyl azodicaboxlate and oxidizing the product of the first step in the presence of an organic radical catalyst:Type: GrantFiled: September 28, 2001Date of Patent: July 23, 2002Assignee: Hanmi Pharm. Co., Ltd.Inventors: Young-Ho Moon, Kyung-Ik Lee, Gwan-Sun Lee
-
Patent number: 6410569Abstract: The invention relates to the dihydrate of the magnesium salt of pantoprazole.Type: GrantFiled: February 8, 2001Date of Patent: June 25, 2002Assignee: Byk Gulden Lomberg Chemische Fabrik GmbHInventor: Bernhard Kohl
-
Patent number: 6403582Abstract: Compound represented by the structural formula or a pharmaceutically acceptable salt thereof, wherein: a is 0-3; b, d and e are 0-2; R is H, alkyl, F or —OR6; A is an optionally substituted oxime or hydrazone; d is not 0 and X is a bond, —C(O)—, —O—, —NR9—, —S(O)e—, —N(R6)C(O)—, —C(O)N(R6)—, —OC(O)NR6—, —OC(═S)NR6—, —N(R6)C(═S)O—, —S(O)2N(R6)—, —N(R6)S(O)2—, —N(R6)C(O)O—, —OC(O)— or —N(R6)C(O)NR7—; or d is 0 and X is a bond or —NR6—; T is H, aryl, heterocycloalkyl or heteroaryl; Q is phenyl, naphthyl or heteroaryl; R6 is H, alkyl, hydroxyalkyl, alkoxyalkyl, phenyl, and benzyl; R9 is R6 or —OR6 R6a, R7a, R8a and R9a are H or alkyl; Z is a nitrogen-containing heterocyclo group, e.g.Type: GrantFiled: January 12, 2001Date of Patent: June 11, 2002Assignee: Schering CorporationInventors: Gregory A. Reichard, Neng-Yang Shih, Dasong Wang
-
Patent number: 6403616Abstract: Process for the manufacturing of slightly soluble or less soluble alkaline salts of substituted sulphinyl heterocycles containing an imidazole moiety with formula I preferably alkaline salts of a proton pump inhibitor compound, wherein the process comprises the step of reacting the substituted sulphinyl heterocycle of Formula I with a source of the cation in the presence of a base, characterized by a washing step in which the prepared alkaline salt of the substituted sulphinyl compound is washed with a basic aqueous solvent mixture. The obtained bulk drug substance resulting in a bulk product that in an aqueous suspension of the substituted sulphinyl heterocycle having a pH not significantly lower than that of a saturated water solution of the pure compound prepared. Alternatively, the process for manufacturing a pharmaceutical dosage form comprising the active substance could be adjusted.Type: GrantFiled: February 17, 2000Date of Patent: June 11, 2002Assignee: AstraZeneca ABInventors: Magnus Erickson, Anders Gustavsson, Lars Josefsson
-
Patent number: 6384059Abstract: The present invention relates to a novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl-1H-benzimidazole, known under the generic name omeprazole. Further, the present invention also relates to the use of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole.Type: GrantFiled: August 15, 2000Date of Patent: May 7, 2002Assignee: AstraZëneca ABInventors: Karin Lövqvist, Gunnel Sundén, David Noreland, Ingvar Ymén
-
Patent number: 6369085Abstract: The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: GrantFiled: June 8, 1998Date of Patent: April 9, 2002Assignee: AstraZeneca ABInventors: Hanna Cotton, Anders Kronström, Anders Mattson, Eva Möller
-
Patent number: 6350876Abstract: 2-Sulfonylpyridine derivatives can be industrially produced efficiently by reacting a sulfonyl cyanide derivative with an &agr;,&bgr;-unsaturated carbonyl compound and a 2-{[(2-pyridyl)methyl]thio}-1H-benzimidazole skeleton can be formed in one step in a good yield by reacting this type of the 2-sulfonylpyridine derivative with a 2-methylthio-1H-benzimidazole derivative in the presence of an organolithium compound.Type: GrantFiled: December 7, 2000Date of Patent: February 26, 2002Assignee: Kuraray Co., Ltd.Inventors: Ken-ichi Koyakumaru, Takashi Sugioka, Tomoya Kuwayama, Goro Asanuma
-
Publication number: 20020016460Abstract: Disclosed are novel compounds of formula (I): 1Type: ApplicationFiled: August 2, 2001Publication date: February 7, 2002Inventors: Roger John Snow, Mario Cardozo, Daniel Goldberg, Abdelhakim Hammach, Tina Morwick, Neil Moss, Usha R. Patel, Anthony S. Prokopowicz, Hidenori Takahashi, Matt Aaron Tschantz, Xiao-Jun Wang
-
Publication number: 20020007069Abstract: An improved process of synthesis of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl-1H-benzimidazole (omeprazole) by oxidation of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole with 3-chloroperoxybenzoic acid in ethyl acetate wherein omeprazole is poorly soluble, at a temperature between −10° C. and 5° C. is disclosed. The second step is a purification of the crude product by dissolution and reprecipitation of the final product.Type: ApplicationFiled: July 30, 2001Publication date: January 17, 2002Inventors: Natasa Hafner Milac, Darja Jereb
-
Patent number: 6323038Abstract: In view of the situation of the prior art, the present invention specifies the structure of a late-stage product of Mailard reaction in vivo having a close relation with various tissue disorders, and provides a diagnostic reagent for complications associated with diabetes or renal failure, containing the above compound as a main component.Type: GrantFiled: January 14, 2000Date of Patent: November 27, 2001Assignee: Asai Germanium Research Institute Co., Ltd.Inventors: Tomoko Oya, Hiroyuki Kobayashi, Mitsuo Akiba, Norihiro Kakimoto, Yasujiro Morimitsu, Toshihiko Osawa
-
Patent number: 6316482Abstract: This invention relates to new benzamide derivatives having a vasopressin antagonistic activity, etc. and represented by general formula (I): wherein R1 is aryl optionally substituted with lower alkoxy, etc., R2 is lower alkyl, etc., R3 is hydrogen, etc., A is NH, etc., E is etc., X is —CH═CH—, —CH═N—, or S, and Y is a condensed heterocyclic group, etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof and to a pharmaceutical composition comprising the same.Type: GrantFiled: July 11, 2000Date of Patent: November 13, 2001Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Hiroyuki Setoi, Takehiko Ohkawa, Tatsuya Zenkoh, Hitoshi Sawada, Yuki Sawada, Teruo Oku
-
Patent number: 6303788Abstract: The present invention relates to a novel process for the synthesis of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, known under the generic name omeprazole. Moreover, the present invention also relates to manufacture of a pharmaceutical preparation thereof and its use in medicine. The novel process for the preparation of omeprazole, comprises the step of oxidizing 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole in an organic solvent with an oxidizing agent in the presence of a titanium complex and optionally in the presence of a base.Type: GrantFiled: December 1, 1998Date of Patent: October 16, 2001Assignee: AstraZeneca ABInventors: Hanna Cotton, Magnus Larsson, Anders Mattson
-
Publication number: 20010025107Abstract: Methods and compositions are disclosed utilizing optically pure (−) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Lansoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.Type: ApplicationFiled: May 11, 2001Publication date: September 27, 2001Inventors: Timothy J. Barberich, William E. Yelle, Paul D. Rubin
-
Publication number: 20010011092Abstract: Novel compounds of the formula 1Type: ApplicationFiled: January 25, 2001Publication date: August 2, 2001Inventors: Deen Tulshian, Ginny D. Ho, Lisa S. Silverman, Julius J. Matasi, Robbie L. McLeod, John A. Hey, Richard W. Chapman, Ana Bercovici, Francis M. Cuss
-
Patent number: 6268502Abstract: An improved process of synthesis of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl-1H-benzimidazole (omeprazole) by oxidation of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole with 3-chloroperoxy-benzoic acid in ethyl acetate wherein omeprazole is poorly soluble, at a temperature between −10° C. and 5° C. is disclosed. The second step is a purification of the crude product by dissolution and reprecipitation of the final product.Type: GrantFiled: August 30, 2000Date of Patent: July 31, 2001Assignee: LEK, Tovarna Farmacevtskih in Kemicnih Izdelkov. D.D.Inventors: Nata{haeck over (s)}a Hafner Mila{haeck over (c)}, Darja Jereb
-
Patent number: 6265349Abstract: The present invention relates to pyridone derivatives and herbicidal compositions containing the pyridone derivatives as active ingredients.Type: GrantFiled: October 27, 1999Date of Patent: July 24, 2001Assignees: Kumiai Chemical Industry Co., Ltd, Ihara Chemical Industry Co., Ltd.Inventors: Mikio Yamaguchi, Yoshihiro Ito, Atsushi Shibayama, Yoshihiro Yamaji, Ryo Hanai, Sota Uotsu, Hideo Sadohara
-
Patent number: 6265581Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.Type: GrantFiled: April 17, 2000Date of Patent: July 24, 2001Assignee: Eli Lilly and CompanyInventors: Michael Gregory Bell, Thomas Alan Crowell, Christine Ann Droste, Cynthia Darshini Jesudason, Donald Paul Matthews, John Hampton McDonald, III, David Andrew Neel, Christopher John Rito, Anthony John Shuker, Mark Alan Winter
-
Patent number: 6248758Abstract: A pharmaceutical formulation comprising a benzimidazole derivative as active ingredient, and as excipients, at least one cyclodextrin and at least one amino acid.Type: GrantFiled: September 8, 1999Date of Patent: June 19, 2001Assignee: Hexal AGInventors: Karin Klokkers, Marion Kutschera, Wilfried Fischer
-
Patent number: 6245913Abstract: The present invention relates to an efficient process for the preparation of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylthio]-1-H-benzimidazole hydrochloride starting from 3,5-Lutidine and its conversion to Omeprazole (5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole) by selective oxidation with hydrogen peroxide.Type: GrantFiled: June 30, 1999Date of Patent: June 12, 2001Assignee: Wockhardt Europe LimitedInventors: Shiva P. Singh, Siddiqui Mohammed Jaweed Mukarram, Dilip Ganesh Kulkami, Manish Purohit
-
Patent number: 6197962Abstract: 2-Sulfonylpyridine derivatives can be industrially produced efficiently by reacting a sulfonyl cyanide derivative with an &agr;, &bgr;-unsaturated carbonyl compound and a 2-{[(2-pyridyl)methyl]thio}-1H-benzimidazole skeleton can be formed in one step in a good yield by reacting this type of the 2-sulfonylpyridine derivative with a 2-methylthio-1H-benzimidazole derivative in the presence of an organolithium compound.Type: GrantFiled: January 25, 1999Date of Patent: March 6, 2001Assignee: Kuraray Co., Ltd.Inventors: Ken-ichi Koyakumaru, Takashi Sugioka, Tomoya Kuwayama, Goro Asanuma
-
Patent number: 6191148Abstract: The present invention describes an improved process for the preparation, isolation, and purification of the anti-ulcer agent omeprazole whereby the sulfide precursor pyrmetazole is reacted subsurfacely with exactly one molar equivalent of meta-chloroperoxybenzoic acid in a chlorinated aliphatic hydrocarbon or aromatic hydrocarbon solvent, such as methylene chloride or toluene; residual organic solvent is removed from the aqueous layer by vacuum distillation; crude product is obtained by reactive crystallization with an alkyl formate or formic acid solution and seeding; and pure product is isolated by recrystallization in methanol-water containing aqueous NaOH by subsurface addition of aqueous acetic acid to pH 9.0, seeding, filtration, washing, and drying. Omeprazole and compositions of omeprazole containing no chromatographically detectable levels of residual non-alcoholic organic reaction solvent and diminished levels of alcoholic solvent are also described.Type: GrantFiled: December 15, 1999Date of Patent: February 20, 2001Assignee: Merck & Co., Inc.Inventors: James W. McManus, Nick Anousis, Benjamin Newton Banks, Hui Liu, Lingwen Zhou
-
Patent number: 6180652Abstract: The present invention provides acetone complexes of sulfoxide compounds, useful as medicines such as inhibitors of gastric acid secretion and anti-ulcer agents or as intermediates for production of medicines, a process for producing the same and a purification method of using the same. Namely, it is the acetone complexes of sulfoxide compounds or of pharmaceutically acceptable salts thereof represented by the following formula: (wherein R1 represents a hydrogen atom, a methoxy group or a difluoromethoxy group, R2 represents a methyl group or a methoxy group, R3 represents a 3-methoxypropoxy group, a methoxy group or a 2,2,2-trifluoroethoxy group, R4 represents a hydrogen atom or a methyl group, n and m independently represent an integer of 1 to 4, and B represents a hydrogen atom, an alkali metal atom or ½ alkaline earth metal atom), which are obtained by treating the sulfoxide compounds or pharmaceutically acceptable salts thereof with acetone.Type: GrantFiled: November 3, 1999Date of Patent: January 30, 2001Assignee: Eisai Co., Ltd.Inventors: Masahiko Tsujii, Nobuo Niikawa, Keizo Takayanagi, Shigeharu Nochi